Cargando…
Adjunctive treatment with aripiprazole for olanzapine-induced hyperprolactinemia
INTRODUCTION: Hyperprolactinemia is a common unwanted antipsychotic-induced adverse effect, particularly in female patients, and can induce poor adherence to treatment. Aripiprazole is an antipsychotic with partial agonist activity over the dopamine D2 receptors which can be effective in reducing hy...
Autores principales: | Bise, S., Sulejmanpasic, G., Hrnjica, A., Šarkić-Bedak, Š. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567633/ http://dx.doi.org/10.1192/j.eurpsy.2022.2003 |
Ejemplares similares
-
COVID- 19 Following Acute Psychosis: Case series report
por: Hrnjica, A., et al.
Publicado: (2022) -
Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia
por: Ranjbar, Fatemeh, et al.
Publicado: (2015) -
Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole
por: Kotorki, Paraskevi, et al.
Publicado: (2010) -
Adjunctive Aripiprazole Versus Placebo for Antipsychotic-Induced Hyperprolactinemia: Meta-Analysis of Randomized Controlled Trials
por: Li, Xianbin, et al.
Publicado: (2013) -
PM403. Comparison between addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia
por: Lee, Jung Suk, et al.
Publicado: (2016)